Akers Biosciences Inc. (AKER): Price and Financial Metrics
AKER Price/Volume Stats
| Current price | $4.94 | 52-week high | $6.97 |
| Prev. close | $2.73 | 52-week low | $1.65 |
| Day low | $4.81 | Volume | 791,750 |
| Day high | $6.08 | Avg. volume | 769,876 |
| 50-day MA | $3.32 | Dividend yield | N/A |
| 200-day MA | $3.03 | Market Cap | 82.27M |
AKER Stock Price Chart Interactive Chart >
Akers Biosciences Inc. (AKER) Company Bio
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
Latest AKER News From Around the Web
Below are the latest news stories about Akers Biosciences Inc that investors may wish to consider to help them evaluate AKER as an investment opportunity.
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of MergerAkers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger |
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression TrialAkers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. |
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory BoardAkers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. |
We Think Akers Biosciences (NASDAQ:AKER) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing InvestigationsTilray, Inc. (NASDAQ: TLRY) |
AKER Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -87.65% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -37.81% |
| 2019 | -88.20% |
Continue Researching AKER
Want to see what other sources are saying about Akers Biosciences Inc's financials and stock price? Try the links below:Akers Biosciences Inc (AKER) Stock Price | Nasdaq
Akers Biosciences Inc (AKER) Stock Quote, History and News - Yahoo Finance
Akers Biosciences Inc (AKER) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...